Reach the biopharma world with the Endpoints platform.

Unleash revenue potential via lead generation
Raise your company profile with custom content
Spark brand recognition with our highly specific audience
Amplify your company as a champion on key industry topics

325,000 UNIQUE MONTHLY READERS

55,100 DAILY EMAIL SUBSCRIBERS

2,000 EVENT ATTENDEES

About Endpoints

Since launching June 2016, Endpoints News has become the way drug development executives stay informed. Reported by a global team of journalists — led by founder John Carroll — Endpoints covers news as it happens and delivers an inimitable twice-daily email report to an engaged audience in the business of discovering, researching, marketing, and regulating biotech drugs.

We convene this audience to hear from news-makers firsthand at four global events — San Francisco, Boston, London and Shanghai — bringing journalistic excellence to life and providing qualified sponsors with premium brand opportunities. And a slate of webinars throughout the year regularly connects virtual attendees with experts on targeted topics.

​Endpoints is different because we treat our audience to a low-volume of high-quality advertising from qualified biopharma sponsors, partnered with our expert business team. That approach rewards both our clients with superior results while readers enjoy a premium reading experience.

We invite you to schedule a conversation with our team. Whether your goal is branding, generating leads, or educating the market, Endpoints can help you reach your target audience effectively and in style.

Whether your goal is generating new business, creating brand awareness, or educating the market, Endpoints can help target your ideal audience.

  • CLOSELY READ BY ELITE PROS AT EVERY TOP 25 PHARMA R&D SPENDER & THOUSANDS OF BIOTECH STARTUPS

  • POWERED BY OUR INDEPENDENT JOURNALISM, FUNDED ENTIRELY BY SUBSCRIBERS AND CLIENTS

  • EACH CAMPAIGN WITH ENDPOINTS COMES WITH THE METRICS YOU NEED TO TEST AND JUSTIFY YOUR ROI

readership

Audience

  • 23% clinical biotech
  • 22% big biopharma
  • 14% preclinical biotech
  • 9% cro
  • 8% mid/specialty pharma
  • 5% vc/biotech finance
  • 5% cdmo
  • 4% bio it/technology
  • 4% other biopharma
  • 3% consulting
  • 3% academia

Job Function

  • 36% executive management
  • 23% clinical r&d
  • 17% business development
  • 6% consultant
  • 5% lab scientist
  • 5% finance
  • 4% bioinformatics
  • 4% regulatory affairs

Advertising on the uncluttered Endpoints platform allows biopharma brands to stand out like nowhere else. Read daily by thousands of business and science leaders engaged in drug R&D around the world, your sponsorship will be presented to the C-suite and to legions of team players who make biopharma turn. And we have sponsorship packages for all budgets and ambitions.

Top Subscribers Include

  • AC Immune
  • AbbVie
  • Aduro
  • Aimmune
  • Alexion
  • Allergan
  • Allogene
  • Alnylam
  • Amgen
  • Arcturus
  • AstraZeneca
  • Bayer
  • BeiGene
  • BioMarin
  • Bristol-Myers
  • CRISPR
  • Caribou
  • Checkmate
  • Codiak Bio
  • Daiichi Sankyo
  • Decibel
  • Denali
  • EMD Serono
  • Eli Lilly
  • Exelixis
  • Fulcrum
  • GSK
  • Genenta
  • Gilead
  • Harvard
  • Intellia
  • Ionis
  • Ironwood
  • J&J
  • Janssen
  • Lundbeck
  • MD Anderson
  • MIT
  • Merck
  • Moderna
  • Nimbus
  • Novartis
  • Novo Nordisk
  • Pfizer
  • Princeton
  • Proteon
  • Regeneron
  • Relay
  • Roche
  • Roivant
  • Sanofi
  • Scholar Rock
  • Spark
  • Stanford
  • Sutro
  • Takeda
  • Tessa
  • Vertex
  • Voyager
  • Zymeworks

Select Clients